Supernus Pharmaceuticals(US:SUPN) Globenewswireยท2025-04-23 21:14Company Overview - Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases [4]. - The company's diverse neuroscience portfolio includes approved treatments for ADHD, dyskinesia in Parkinson's disease, hypomobility in Parkinson's disease, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [5]. Upcoming Financial Results - The company expects to report financial and business results for the first quarter of 2025 after the market closes on May 6, 2025 [1]. - A conference call will be hosted by Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, on the same day at 4:30 p.m. ET to present these results [2]. Conference Call Details - Participants can pre-register for the conference call and will receive a dial-in number with a personalized conference code [3]. - A live webcast of the call will be available on the company's Investor Relations website, and a replay will be accessible for 60 days following the live call [3].